RxDoctor Payments Data

Shu Yang, MD

Clinical Cardiac Electrophysiology · Boston, MANPI 1588044259

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (43.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Biosense Webster, Inc. at 43.9% of the total. 2025 is the largest year on record at $36,031, more than ten times the $885 reported in 2021.

$80,801in general payments, 2019–2025

Across 155 payments — averaging $521.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$36K
  • Medtronic$21K
  • Boston Scientific$16K
  • Abbott$4K
  • Biotronik Inc.$3K
  • Medical Device Business Services, Inc.$2K
  • plus $60 from 2 others

What the payments were for

  • Consulting fees$32,65040%
  • Grants$35,00043%
  • Travel & lodging$5,6577%
  • Food & beverage$6,4848%
  • Education$1,0101%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,801 in reported general payments places this provider in the 80th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$73,256
Medicare patients
233
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$21,147
Flecainide Acetate11$317
Metoprolol Succinate13$268

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →